Lilly has acquired three companies to expand its infectious disease portfolio. The deals add a better-tolerated shingles vaccine, a bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae, and C. trachomatis, and nanoparticle EBV vaccine technology. The deals include milestone payments.
Insights / Pharma
PharmaLilly acquires three companies to expand infectious disease portfolio
Eli Lilly has acquired three companies to expand its infectious disease portfolio, adding a better-tolerated shingles vaccine, a bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae, and C. trachomatis, and nanoparticle EBV vaccine technology.
